Gland Pharma IPO GMP Today Rate, Gland Pharma IPO Grey Market Premium

Gland Pharma, which is majority owned by China’s Shanghai Fosun Pharmaceutical (Fosun Pharma), has received a crucial nod from market regulator Sebi to launch an initial public offering (IPO) to raise up to Rs 6,000 crore. The company was incorporated in 1978 based in Hyderabad. The company is a manufacturer, marketer, and developer of complex injectables across its seven manufacturing facilities. The price band is fixed at 1490-1500 rupees with 10 shares of minimum bid. As per the price looks on a higher side. The company looks good as the GMP started in green. Check out Gland Pharma IPO grey market premium, Kostak rates, and subject to sauda rates as of today.



Gland Pharma IPO GMP Rates day by day with Kostak rates.

Date GMP Rate Kostak Sauda
06-11-2020 Rs.60-70 Rs.500 Rs. 2000
05-11-2020 Rs.70-80 Rs.500 Rs. 1000
04-11-2020 Rs.150-160 Rs.800 Rs. 1400
03-11-2020 Rs.200 Rs.1250 NA
02-11-2020 Rs. 200 Rs.1250 NA

Gland Pharma IPO Dates & Price Band: (Tentative)

 IPO Open: 09 November 2020
 IPO Close: 11 November 2020
 IPO Size: Approx ₹6480 Crore (Approx)
 Face Value: ₹1 Per Equity Share
 Price Band: ₹1490 - ₹1500 Per Share
 Listing on: BSE & NSE
 Retail Portion: 35%
 Equity: 43,196,968 Shares

Gland Pharma IPO Market Lot:

 Lot Size: Minimum 10 Shares & Maximum 130 Shares
 Minimum Amount: ₹15,000
 Maximum Amount: ₹1,95,000

Gland Pharma IPO Allotment & Listing:

 Basis of Allotment:17 November 2020
 Refunds:18 November 2020
 Credit to Demat Account:19 November 2020
 Listing Date:20 November 2020

Disclaimer:

- IPO Grey Market Premium (IPO GMP) mention is valid for the specific date as mentioned in the header.
- We are not buying and selling IPO forms on IPO Grey Market.
- Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
- Do not subscribe for IPO by just seeing premium Price as it may change anytime before listing. Subscribe only considering Fundamental of the companies


Post a comment

0 Comments